<DOC>
	<DOCNO>NCT00652743</DOCNO>
	<brief_summary>Today , lead contender next influenza pandemic H5N1 , strain avian virus find primarily domestic wild bird . Experts warn next influenza pandemic imminent could severe . Prevention control depend rapid production worldwide distribution specific pandemic vaccine . Candidate 'pandemic-like ' vaccine must develop tested clinical trial determine best formulation vaccination schedule . The purpose study ass immune response candidate pandemic vaccine . The protocol post deal objective &amp; outcome measure secondary phase study . The objective outcome measure primary phase present separate protocol posting ( NCT number = 00449670 ) .</brief_summary>
	<brief_title>Immunogenicity GSK Biologicals ' Pandemic Influenza Vaccine ( GSK1562902A ) Different Boosting Vaccination Schedules</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects complete participation primary phase study . Subjects investigator believe comply requirement protocol enrol study . Written inform consent obtain subject . Healthy subject establish medical history clinical examination enter study . If subject female , must nonchildbearing potential postmenopausal ; childbearing potential , must practice adequate contraception 30 day prior vaccination , negative pregnancy test continue precaution two month completion vaccination series . Administration license vaccine within 4 week prior enrolment study . Planned administration vaccine foreseen study protocol : 4 week prior visit within 30 day vaccination . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first visit plan use study Any confirm suspected immunosuppressive immunodeficient condition , autoimmune disease Guillain Barre Syndrome , base medical history physical examination ( laboratory testing require ) . History hypersensitivity vaccine . History allergic disease reaction likely exacerbate component vaccine . History chronic alcohol consumption and/or drug abuse . Acute clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test . Serious chronic disease include medically significant chronic pulmonary , cardiovascular , renal , neurological , psychiatric metabolic disorder , determine medical history physical examination . Acute disease time enrolment . Administration immunoglobulins and/or blood product within three month precede first visit plan use study . Pregnant lactate woman . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day prior first visit , plan use study period . Any condition , opinion investigator , prevents subject participation study .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>61 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>immunogenicity</keyword>
	<keyword>safety</keyword>
	<keyword>GSK pandemic candidate vaccine</keyword>
</DOC>